Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.61
BIO.B's Cash to Debt is ranked higher than
65% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. BIO.B: 1.61 )
BIO.B' s 10-Year Cash to Debt Range
Min: 0.04   Max: 1.61
Current: 1.61

0.04
1.61
Equity to Asset 0.64
BIO.B's Equity to Asset is ranked higher than
72% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. BIO.B: 0.64 )
BIO.B' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.67
Current: 0.64

0.33
0.67
Interest Coverage 2.77
BIO.B's Interest Coverage is ranked lower than
54% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. BIO.B: 2.77 )
BIO.B' s 10-Year Interest Coverage Range
Min: 2.18   Max: 22.17
Current: 2.77

2.18
22.17
F-Score: 4
Z-Score: 3.63
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.96
BIO.B's Operating margin (%) is ranked higher than
82% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. BIO.B: 6.96 )
BIO.B' s 10-Year Operating margin (%) Range
Min: 6.23   Max: 15.39
Current: 6.96

6.23
15.39
Net-margin (%) 3.67
BIO.B's Net-margin (%) is ranked higher than
79% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. BIO.B: 3.67 )
BIO.B' s 10-Year Net-margin (%) Range
Min: 2.13   Max: 9.63
Current: 3.67

2.13
9.63
ROE (%) 3.64
BIO.B's ROE (%) is ranked higher than
75% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. BIO.B: 3.64 )
BIO.B' s 10-Year ROE (%) Range
Min: 3.71   Max: 20.35
Current: 3.64

3.71
20.35
ROA (%) 2.36
BIO.B's ROA (%) is ranked higher than
77% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. BIO.B: 2.36 )
BIO.B' s 10-Year ROA (%) Range
Min: 2.26   Max: 9.66
Current: 2.36

2.26
9.66
ROC (Joel Greenblatt) (%) 14.32
BIO.B's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. BIO.B: 14.32 )
BIO.B' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 13.54   Max: 43.08
Current: 14.32

13.54
43.08
Revenue Growth (%) 2.50
BIO.B's Revenue Growth (%) is ranked higher than
69% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BIO.B: 2.50 )
BIO.B' s 10-Year Revenue Growth (%) Range
Min: 2.5   Max: 21.6
Current: 2.5

2.5
21.6
EBITDA Growth (%) -7.40
BIO.B's EBITDA Growth (%) is ranked higher than
67% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BIO.B: -7.40 )
BIO.B' s 10-Year EBITDA Growth (%) Range
Min: -7.4   Max: 41.2
Current: -7.4

-7.4
41.2
EPS Growth (%) -25.80
BIO.B's EPS Growth (%) is ranked higher than
61% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. BIO.B: -25.80 )
BIO.B' s 10-Year EPS Growth (%) Range
Min: -25.8   Max: 76.3
Current: -25.8

-25.8
76.3
» BIO.B's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with BIO.B

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 43.30
BIO.B's P/E(ttm) is ranked higher than
82% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO.B: 43.30 )
BIO.B' s 10-Year P/E(ttm) Range
Min: 13.68   Max: 58.63
Current: 43.3

13.68
58.63
P/B 1.58
BIO.B's P/B is ranked higher than
94% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. BIO.B: 1.58 )
BIO.B' s 10-Year P/B Range
Min: 1.44   Max: 3.22
Current: 1.58

1.44
3.22
P/S 1.60
BIO.B's P/S is ranked higher than
86% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. BIO.B: 1.60 )
BIO.B' s 10-Year P/S Range
Min: 0.87   Max: 2.15
Current: 1.6

0.87
2.15
PFCF 19.28
BIO.B's PFCF is ranked higher than
94% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO.B: 19.28 )
BIO.B' s 10-Year PFCF Range
Min: 9.62   Max: 475.33
Current: 19.28

9.62
475.33
EV-to-EBIT 20.96
BIO.B's EV-to-EBIT is ranked higher than
85% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO.B: 20.96 )
BIO.B' s 10-Year EV-to-EBIT Range
Min: 8.3   Max: 23.4
Current: 20.96

8.3
23.4
PEG 7.34
BIO.B's PEG is ranked higher than
87% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO.B: 7.34 )
BIO.B' s 10-Year PEG Range
Min: 0.56   Max: 23.92
Current: 7.34

0.56
23.92
Shiller P/E 24.05
BIO.B's Shiller P/E is ranked higher than
95% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO.B: 24.05 )
BIO.B' s 10-Year Shiller P/E Range
Min: 16.31   Max: 35.92
Current: 24.05

16.31
35.92
Current Ratio 3.50
BIO.B's Current Ratio is ranked higher than
78% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. BIO.B: 3.50 )
BIO.B' s 10-Year Current Ratio Range
Min: 1.87   Max: 4.52
Current: 3.5

1.87
4.52
Quick Ratio 2.48
BIO.B's Quick Ratio is ranked higher than
74% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. BIO.B: 2.48 )
BIO.B' s 10-Year Quick Ratio Range
Min: 1.16   Max: 3.45
Current: 2.48

1.16
3.45

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 201.61
BIO.B's Price/Net Current Asset Value is ranked higher than
77% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO.B: 201.61 )
BIO.B' s 10-Year Price/Net Current Asset Value Range
Min: 17.15   Max: 2402.8
Current: 201.61

17.15
2402.8
Price/Tangible Book 2.47
BIO.B's Price/Tangible Book is ranked higher than
88% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.28 vs. BIO.B: 2.47 )
BIO.B' s 10-Year Price/Tangible Book Range
Min: 1.11   Max: 6.43
Current: 2.47

1.11
6.43
Price/DCF (Projected) 1.08
BIO.B's Price/DCF (Projected) is ranked higher than
96% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO.B: 1.08 )
BIO.B' s 10-Year Price/DCF (Projected) Range
Min: 0.79   Max: 17.92
Current: 1.08

0.79
17.92
Price/Median PS Value 1.07
BIO.B's Price/Median PS Value is ranked higher than
81% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. BIO.B: 1.07 )
BIO.B' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 1.31
Current: 1.07

0.25
1.31
Price/Graham Number 2.18
BIO.B's Price/Graham Number is ranked higher than
91% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BIO.B: 2.18 )
BIO.B' s 10-Year Price/Graham Number Range
Min: 0.68   Max: 3.48
Current: 2.18

0.68
3.48
Earnings Yield (Greenblatt) 4.80
BIO.B's Earnings Yield (Greenblatt) is ranked higher than
85% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. BIO.B: 4.80 )
BIO.B' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.3   Max: 12
Current: 4.8

4.3
12
Forward Rate of Return (Yacktman) 0.99
BIO.B's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. BIO.B: 0.99 )
BIO.B' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.7   Max: 29.3
Current: 0.99

1.7
29.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:BUWA.Germany
Bio-Rad Laboratories Inc was founded in 1952 and incorporated in 1957. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates in two industry segments designated as Life Science and Clinical Diagnostics. Both segments operate worldwide. Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological questions. The Company is engaged in developing, manufacturing and marketing a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a global customer base. Many of its products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. Its main life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. Its products currently address specific niches within the in vitro diagnostics (IVD) test market. It supplies more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient's tissue, blood or urine. Its products consist of reagents, instruments and software, typically provided to its customers as an integrated package to allow them to generate reproducible test results. Its main clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories. The Company owns numerous U.S. and international patents and patent licenses. Each of the Company's segments maintains a sales force to sell its products on a direct basis. Major competitors in the clinical diagnostic segment include Roche, Abbott Laboratories (Diagnostic Division), Siemens Medical Diagnostics Solutions (formerly Dade-Behring, Diagnostics Products Corporation, and Bayer Diagnostics), Beckman Coulter, Becton-Dickinson, bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Thermo Fisher, Tosoh, Immucor, Cepheid, and DiaSorin. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations tha
» More Articles for BIO.B

Headlines

Articles On GuruFocus.com
Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters With U.S. Government Nov 03 2014 
Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014 Oct 15 2014 
Bio-Rad Appoints John Goetz as Chief Operating Officer and Announces Other Executive Appointments Oct 15 2014 
Widely Held Guru Stocks Near Historical Low P/B Ratios Aug 11 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Jun 02 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 27 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 19 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/B May 12 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Apr 23 2014 

More From Other Websites
Bio-Rad Receives Premarket Application Approval for Its Geenius HIV 1/2 Supplemental Assay Nov 18 2014
Bio-Rad posts 3Q profit Nov 04 2014
Bio-Rad posts 3Q profit Nov 04 2014
Bio-Rad Reports Third-Quarter 2014 Financial Results Nov 04 2014
Bio-Rad paying $55M to resolve US bribery claims Nov 03 2014
Bio-Rad paying $55M to resolve US bribery claims Nov 03 2014
Bio-Rad Laboratories Resolves Foreign Corrupt Practices Act Matters With U.S. Government Nov 03 2014
Bio-Rad to Report Third-Quarter 2014 Financial Results Tuesday, November 4, 2014 Oct 08 2014
Bio-Rad Appoints John Goetz as Chief Operating Officer and Announces Other Executive Appointments Oct 01 2014
Bio-Rad Laboratories (BIO.B) Downgraded From Buy to Hold Sep 30 2014
Bio-Rad Reports Second-Quarter 2014 Financial Results Aug 05 2014
Bio-Rad Announces the Appointment of New Board Member Jul 25 2014
Bio-Rad to Report Second-Quarter 2014 Financial Results Tuesday, August 5, 2014 Jul 07 2014
Bio-Rad Launches Vitamin D Kit for Its BioPlex 2200 System Jun 23 2014
Bio-Rad Launches the First Fully-Automated 5th Generation HIV Test Jun 17 2014
Bio-Rad Laboratories Inc Stock Downgraded (BIO.B) Jun 06 2014
Bio-Rad Reports First-Quarter 2014 Financial Results May 06 2014
Bio-Rad Named One of the '2014 Best Places to Work in the Bay Area' Apr 28 2014
Bio-Rad to Report First-Quarter 2014 Financial Results Tuesday, May 6, 2014 Apr 16 2014
Bio-Rad Acquires GnuBIO and DNA Sequencing Technology Apr 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK